Literature DB >> 29076870

Transcatheter device closure of atrial septal defects: more to think about than just closing the hole.

Michael L O'Byrne1,2,3,4, Andrew C Glatz1,2,3, Matthew J Gillespie1,2.   

Abstract

PURPOSE OF REVIEW: To review current controversies in the transcatheter device closure of ostium secundum atrial septal defects (ASD). RECENT
FINDINGS: Transcatheter device closure of ASD (TC-ASD) has well established efficacy and safety. For most individual patients with suitable anatomy, TC-ASD is the preferred method for treating ASD. The availability of large multicenter data sets has made it possible to study practice patterns at a range of hospitals across the United States. These studies have revealed differences in practice that were not previously appreciated. Interpretation of the indications for TC-ASD, specifically the definition of right ventricular volume overload varies between hospitals. In response to concern about device erosion, an increasing proportion of patients are being referred for operative ASD closure. Over the last decade, the average age at which ASD closure occurs has decreased. These trends demonstrate previously underappreciated differences in opinion between cardiologists across the country and suggest that further research is necessary to address knowledge gaps limiting consistency of practice.
SUMMARY: As TC-ASD and congenital interventional cardiology mature as a field, studies of real-world practice provide increasingly valuable information about aspects of care in which there are disagreements about best practices and in which further research is necessary.

Entities:  

Mesh:

Year:  2018        PMID: 29076870      PMCID: PMC6112166          DOI: 10.1097/HCO.0000000000000476

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  79 in total

Review 1.  Erosions, erosions, and erosions! Device closure of atrial septal defects: how safe is safe?

Authors:  Karim Diab; Damien Kenny; Ziyad M Hijazi
Journal:  Catheter Cardiovasc Interv       Date:  2012-08-01       Impact factor: 2.692

2.  Recent changes in instructions for use for the Amplatzer atrial septal defect occluder: how to incorporate these changes while using transesophageal echocardiography or intracardiac echocardiography?

Authors:  Kiran Mallula; Zahid Amin
Journal:  Pediatr Cardiol       Date:  2012-05-11       Impact factor: 1.655

3.  Transcatheter closure of secundum atrial septal defects: has fear of device erosion altered outcomes?

Authors:  Bryan Mitchelson; Clare O'Donnell; Peter Ruygrok; John Wright; John Stirling; Nigel Wilson
Journal:  Cardiol Young       Date:  2017-01-12       Impact factor: 1.093

4.  Natural history of growth of secundum atrial septal defects and implications for transcatheter closure.

Authors:  C J McMahon; T F Feltes; J K Fraley; J T Bricker; R G Grifka; T A Tortoriello; R Blake; L I Bezold
Journal:  Heart       Date:  2002-03       Impact factor: 5.994

5.  Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program).

Authors:  Paul S Chan; Thomas M Maddox; Fengming Tang; Sarah Spinler; John A Spertus
Journal:  Am J Cardiol       Date:  2011-07-26       Impact factor: 2.778

6.  Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Authors:  Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen
Journal:  Eur Heart J       Date:  2005-04-12       Impact factor: 29.983

7.  Adherence to guidelines in the clinical care for adults with congenital heart disease: the Euro Heart Survey on adult congenital heart disease.

Authors:  Peter Engelfriet; Jan Tijssen; Harald Kaemmerer; Michael A Gatzoulis; Eric Boersma; Erwin Oechslin; Erik Thaulow; Jana Popelová; Philip Moons; Folkert Meijboom; Luciano Daliento; Rafael Hirsch; Valérie Laforest; Ulf Thilén; Barbara Mulder
Journal:  Eur Heart J       Date:  2006-01-09       Impact factor: 29.983

8.  The influence of deficient retro-aortic rim on technical success and early adverse events following device closure of secundum atrial septal defects: An Analysis of the IMPACT Registry®.

Authors:  Michael L O'Byrne; Matthew J Gillespie; Kevin F Kennedy; Yoav Dori; Jonathan J Rome; Andrew C Glatz
Journal:  Catheter Cardiovasc Interv       Date:  2016-05-18       Impact factor: 2.692

9.  Community use of the amplatzer atrial septal defect occluder: results of the multicenter MAGIC atrial septal defect study.

Authors:  Allen D Everett; Jacky Jennings; Erica Sibinga; Carl Owada; D Scott Lim; John Cheatham; Ralf Holzer; Jeremy Ringewald; Rani Bandisode; Richard Ringel
Journal:  Pediatr Cardiol       Date:  2008-11-18       Impact factor: 1.655

10.  An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program.

Authors:  William R Lewis; Eric D Peterson; Christopher P Cannon; Dennis M Super; Kenneth A LaBresh; Kathleen Quealy; Li Liang; Gregg C Fonarow
Journal:  Arch Intern Med       Date:  2008-09-08
View more
  3 in total

Review 1.  Transcatheter Occluder Devices for the Closure of Atrial Septal Defect in Children: How Safe and Effective Are They? A Systematic Review.

Authors:  Tejasvi Kashyap; Muhammad Sanusi; Elina S Momin; Asma A Khan; Vijayalakshmi Mannan; Muhammad Ahad Pervaiz; Aqsa Akram; Abeer O Elshaikh
Journal:  Cureus       Date:  2022-05-27

2.  A Novel Wire Is Effective for Echo-Guiding Percutaneous Atrial Septal Defect Closure: A Preclinical Study.

Authors:  Yao Liu; Gai-Li Guo; Feng-Wen Zhang; Bin Wen; Wen-Bin Ou-Yang; Yong-Quan Xie; Xiang-Bin Pan
Journal:  J Healthc Eng       Date:  2018-07-03       Impact factor: 2.682

3.  Comparison of Postoperative Changes in Inflammatory Marker Levels Between Transthoracic and Transcatheter Device Closures of Atrial Septal Defects in Children.

Authors:  Zhi-Nuan Hong; Jiang-Shan Huang; Kai-Peng Sun; Zeng-Rong Luo; Qiang Chen
Journal:  Braz J Cardiovasc Surg       Date:  2020-08-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.